Terms: = Kidney tumors AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Treatment
24 results:
1. CHRM4/AKT/mycn upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.
Wen YC; Tram VTN; Chen WH; Li CH; Yeh HL; Thuy Dung PV; Jiang KC; Li HR; Huang J; Hsiao M; Chen WY; Liu YN
Cell Death Dis; 2023 May; 14(5):304. PubMed ID: 37142586
[TBL] [Abstract] [Full Text] [Related]
2. Targeting PKLR/mycn/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
[TBL] [Abstract] [Full Text] [Related]
3. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Schultz CR; Swanson MA; Dowling TC; Bachmann AS
Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
[TBL] [Abstract] [Full Text] [Related]
4. Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
Valind A; Gisselsson D
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1397. PubMed ID: 33932141
[TBL] [Abstract] [Full Text] [Related]
5. The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma.
Li X; Hou G; Zhu Z; Yan F; Wang F; Wei D; Zheng Y; Yuan J; Zheng W; Zhang G; Meng P; Guo Y; Li X; Yao L; Shen L; Yuan J
Invest New Drugs; 2020 Aug; 38(4):956-966. PubMed ID: 31463638
[TBL] [Abstract] [Full Text] [Related]
6. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
[TBL] [Abstract] [Full Text] [Related]
7. Case report: value of gene expression profiling in the diagnosis of atypical neuroblastoma.
Harttrampf AC; Chen Q; Jüttner E; Geiger J; Vansant G; Khan J; Kontny U
BMC Res Notes; 2017 Aug; 10(1):413. PubMed ID: 28818093
[TBL] [Abstract] [Full Text] [Related]
8. Gain of 1q As a Prognostic Biomarker in Wilms tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
[TBL] [Abstract] [Full Text] [Related]
9. Genetic and chromosomal alterations in Kenyan Wilms Tumor.
Lovvorn HN; Pierce J; Libes J; Li B; Wei Q; Correa H; Gouffon J; Clark PE; Axt JR; Hansen E; Newton M; O'Neill JA;
Genes Chromosomes Cancer; 2015 Nov; 54(11):702-15. PubMed ID: 26274016
[TBL] [Abstract] [Full Text] [Related]
10. N‑Myc downstream‑regulated gene 2 suppresses proliferation and induces oncosis of OS‑RC‑2 human renal cancer cells.
Liao H; Wu Z; Huang X; Qiu Z; Wu H
Mol Med Rep; 2015 Feb; 11(2):1240-5. PubMed ID: 25373306
[TBL] [Abstract] [Full Text] [Related]
11. Retinoic acid pathway activity in Wilms tumors and characterization of biological responses in vitro.
Wegert J; Bausenwein S; Kneitz S; Roth S; Graf N; Geissinger E; Gessler M
Mol Cancer; 2011 Nov; 10():136. PubMed ID: 22067876
[TBL] [Abstract] [Full Text] [Related]
12. Primary renal neuroblastoma--a clinical pathologic study of 8 cases.
Fan R
Am J Surg Pathol; 2012 Jan; 36(1):94-100. PubMed ID: 21989352
[TBL] [Abstract] [Full Text] [Related]
13. [Neonatal neuroblastoma and prenatal diagnosis].
Messina M; Di Maggio G; Garzi A; Molinaro F; Amato G; Ferrara F
Minerva Pediatr; 2009 Jun; 61(3):349-54. PubMed ID: 19461577
[TBL] [Abstract] [Full Text] [Related]
14. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors.
Wittmann S; Wunder C; Zirn B; Furtwängler R; Wegert J; Graf N; Gessler M
Genes Chromosomes Cancer; 2008 May; 47(5):386-95. PubMed ID: 18260125
[TBL] [Abstract] [Full Text] [Related]
15. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters.
Zirn B; Hartmann O; Samans B; Krause M; Wittmann S; Mertens F; Graf N; Eilers M; Gessler M
Int J Cancer; 2006 Apr; 118(8):1954-62. PubMed ID: 16287080
[TBL] [Abstract] [Full Text] [Related]
16. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
[TBL] [Abstract] [Full Text] [Related]
17. Neuroblastoma preoperatively treated as nephroblastoma: does inadequate therapy worsen the prognosis?
Hero B; Graf N; Simon T; Weirich A; Tröger J; Berthold F
Klin Padiatr; 2002; 214(4):157-61. PubMed ID: 12165895
[TBL] [Abstract] [Full Text] [Related]
18. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma.
Azuhata T; Scott D; Takamizawa S; Wen J; Davidoff A; Fukuzawa M; Sandler A
J Pediatr Surg; 2001 Dec; 36(12):1785-91. PubMed ID: 11733907
[TBL] [Abstract] [Full Text] [Related]
19. Risk-based management: current concepts of treating malignant solid tumors of childhood.
Grosfeld JL
J Am Coll Surg; 1999 Oct; 189(4):407-25. PubMed ID: 10509467
[TBL] [Abstract] [Full Text] [Related]
20. All-trans-retinoic acid-induced growth suppression of blastemal Wilms' tumor.
Vincent TS; Re GG; Hazen-Martin DJ; Tarnowski BI; Willingham MC; Garvin AJ
Pediatr Pathol Lab Med; 1996; 16(5):777-89. PubMed ID: 9025876
[TBL] [Abstract] [Full Text] [Related]
[Next]
